Cell Therapy Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Cell Therapy stocks.

Cell Therapy Stocks Recent News

Date Stock Title
May 15 MRKR Marker Therapeutics GAAP EPS of -$0.27 misses by $0.02, revenue of $1.24M
May 15 MRKR Marker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
May 15 ALLO Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket
May 15 BCDA BioCardia Inc (BCDA) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress Amid ...
May 15 BCDA BioCardia, Inc. (BCDA) Q1 2024 Earnings Call Transcript
May 14 BCDA BioCardia GAAP EPS of -$0.09, revenue of $0.05M
May 14 BCDA BioCardia Reports First Quarter 2024 Business Highlights and Financial Results
May 14 ALLO Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
May 14 LEGN Legend Biotech's Carvykti Faces Stiff Challenges Despite Advances
May 14 IMTX Immatics reports Q1 results
May 14 IMTX Immatics Announces First Quarter 2024 Financial Results and Business Update
May 14 BCDA Most Shareholders Will Probably Find That The Compensation For BioCardia, Inc.'s (NASDAQ:BCDA) CEO Is Reasonable
May 14 ALLO Allogene Therapeutics Inc (ALLO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
May 14 LEGN Legend Biotech Corp (LEGN) Q1 2024 Earnings Call Transcript Highlights: Soaring CARVYKTI Sales ...
May 14 LEGN Q1 2024 Legend Biotech Corp Earnings Call
May 13 ALLO Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript
May 13 ALLO Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
May 13 ALLO Allogene Therapeutics announces pricing of $110M offering of common stock
May 13 ALLO Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
May 13 ALLO Allogene Therapeutics GAAP EPS of -$0.38 beats by $0.03
Cell Therapy

Cell therapy (also called cellular therapy or cytotherapy) is therapy in which cellular material is injected into a patient; this generally means intact, living cells. For example, T cells capable of fighting cancer cells via cell-mediated immunity may be injected in the course of immunotherapy.
Cell therapy originated in the nineteenth century when scientists experimented by injecting animal material in an attempt to prevent and treat illness. Although such attempts produced no positive benefit, further research found in the mid twentieth century that human cells could be used to help prevent the human body rejecting transplanted organs, leading in time to successful bone marrow transplantation.Today two distinct categories of cell therapy are recognized.The first category is cell therapy in mainstream medicine. This is the subject of intense research and the basis of potential therapeutic benefit. Such research can be controversial when it involves human embryonic material.
The second category is in alternative medicine, and perpetuates the practice of injecting animal materials in an attempt to cure disease. This practice, according to the American Cancer Society, is not backed by any medical evidence of effectiveness, and can have deadly consequences.

Browse All Tags